Upload
magdalene-harrington
View
218
Download
0
Tags:
Embed Size (px)
Citation preview
1
Richard CarterHead of Industry Sponsorship
Department of HealthLondon
2
Presentation
Co-operation of public authorities and industry: why is it necessary to work together?
The UK experience
3
Outline of the presentation
The DH role in co-ordinating policy Our aim and why we do this How we go about it
- Pharmaceuticals
- Medical technology Characteristics of the relationship
5
Our aim:
The Government's strategy is to build on the UK’s reputation as being a leader in life sciences, and to work
with both industries to improve the environment for them to continue to innovate.
6
Importance of these industries to the economy of the UK
Vital role of each sector in supporting Government’s health goals and policies
Importance of innovation to health care reform
Why do we do this?
7
Pharmaceutical & Medical Technology sectors in the UK
Pharmaceutical Industry Invests over £3bn annually in
R&D in the UK £12bn of medicines exported
from the UK annually 68,000 directly employed by
the pharmaceutical industry 16 of the worlds top-selling 75
medicines discovered in the UK
Medical technology Annual output is in the region
of £4bn including £2.2bn to the NHS
Exports are about £2bn 55,000 directly employed by
the medical technology industry
8
How do we go about it? – Pharmaceuticals
History of the relationship is long Since 1999 more systematic architecture of engagement 1999-2001 PICTF 2001-present MISG MISG - industry side membership global, government
side ministers and top officials Meets twice a year Joint consideration of strategic issues of common
interest, e.g. science education
9
Close Dialogue & Partnership with Industry-MISG & Long Term Leadership Strategy
Ministerial Industry Strategy Group (MISG)
MISG has overseen the development of the Long Term Leadership Strategy for Medicines (LTLS) which is designed to:
secure the provision of safe and effective medicines for patients;
maintain and strengthen the UK pharmaceutical industry within Europe;
and to advance healthcare innovation in the UK.
10
Close Dialogue & Partnership with Industry- MISG - Long Term Leadership Strategy
Three workstreams have reported on their conclusions:
Partnership Working Group: Dealing with the industry’s relationships with the NHS in England and with uptake of cost effective medicines
European Working Group: Improving the business and technology environment for the pharmaceutical industry in Europe
Regulatory Working Group: Developing the regulatory environment in the UK and Europe so as better to serve needs of all stakeholders
11
Pharmaceuticals - LTLS Report February 2007
12
How do we go about it – Medical Technology
Shorter history of joint engagement Healthcare Industries Task Force (HITF) a year long joint Initiative was set up in 2003 Beginning of an important dialogue between Government and the sector Implementation of its key outputs from 2004 New strategic group – Ministerial Medical Technology Strategy Group – set up to take forward recommendations Will meet twice a year Will consider strategic issues of common interest, e.g. small business support in this sector, innovation
13
Key outputs of HITF
Integration of technology evaluation into procurement - Centre for Evidence-based Purchasing (CEP) Establishment of a National Innovation Centre (NIC) Strengthened R&D environment for medical technologies Streamlined procurement process Continuing shared strategic agenda and architecture within
which to pursue it
14
Medical Technology - Published Reports 2004 and 2007
Further details are available on: www.advisorybodies.doh.gov.uk/hitf
15
Characteristics of the relationships
Well established long term engagement Very senior representation from both sides on the two
joint government/industry groups Genuine interest on both sides in holding constructive
dialogue at strategic level Openness and transparency Ability to disagree without rupturing the connection Strong horizontal working across relevant government
departments
16
The UK Government pharmaceuticalpharmaceutical & medical technologymedical technology Industry linkages: a schematic overview
DHCo-ordination
& policy/ Purchaser/NHS
MHRAEU medicines/device
legislationNICE
Appraisals ofNew technologies
HOAnimal rights
legislation
HMTTax incentives/Science strategy
DBERRScience base
FCO/UKTIInward investment
DFIDAccess to medicines
UKCRCTranslational
Clinical research
OSCHRHealth research
NHS PASAProcurement,
device evaluation
PharmaceuticalsMedical Technology
NHSIII/NIC
DIUSSkills
17
Key Messages
Government committed to a strong relationship with industry
Both parties to the relationship benefit
Working in partnership wherever possible has enabled us to achieve many shared goals